| DC74609 |
9-Deazaguanine |
9-Deazaguanine is a nucleoside analog with potent inhibitory activity against purine nucleoside phosphorylase (PNP). |
|
| DC74610 |
XY-52 |
XY-52 (Compound 32) is a Stimulation-2 (ST2) inhibitor, with an IC50 value of 5.68 μM in AlphaLISA assay, and 4.59 μM in HEK-Blue assay. XY-52 increases proinflammatory T-cell proliferation. XY-52 reduces the plasma sST2 and IFNγ biomarkers in the graft versus host disease (GVHD) mice model. |
|
| DC74611 |
Civorebrutinib |
Civorebrutinib (WS-413) is a Bruton's tyrosine kinase inhibitor with antineoplastic effect. |
|
| DC74613 |
Tegomil fumarate |
Tegomil fumarate is an immunomodulator. |
|
| DC74614 |
Ucasareotide dasaroxetan |
Ucasareotide dasaroxetan (SarTATE) is diagnostic agent with antineoplastic effect. |
|
| DC74615 |
BC-05 |
BC-05 is an orally active and potent inhibitor of CD13 and proteasome. BC-05 has an IC50 value of 0.13 μM for human CD13 and an IC50 value of 1.39 μM for the 20S proteasome. BC-05 can be used in multiple myeloma research. |
|
| DC74616 |
BTM-3566 |
BTM-3566 is an OMA1 activator. BTM-3566 activates the mitochondrial stress response. BTM-3566 induces apoptosis in diffuse large B-cell lymphomas (DLBCL) cell lines. |
|
| DC74617 |
Arecaidine hydrobromide |
Arecaidine hydrobromide, a pyridine alkaloid, is a potent GABA uptake inhibitor. Arecaidine hydrobromide is a substrate of H+-coupled amino acid transporter 1 (PAT1, SLC36A1) and competitively inhibits L-proline uptake. |
|
| DC74618 |
Guvacine hydrobromide |
Guvacine hydrobromide, an alkaloid found in the nut of Areca catechu, is a potent GABA uptakp inhibitor. Guvacine hydrobromide inhibits rat GAT-1, rat GAT-2 and rat GAT-3 with IC50 values of 39 μM, 58 μM and 378 μM, respectively. |
|
| DC74619 |
Ancistrotecine B |
Ancistrotecine B (Compound 2) is a Nav1.7 channel inhibitor (IC50: 0.73 μM). Ancistrotecine B relieves inflammatory pain in mice. |
|
| DC74620 |
OATD-02 |
OATD-02 is an orally active, competitive, reversible, noncovalent dual inhibitor of Arginase1 and 2. OATD-02 is a slow offset inhibitor, blocking intracellular arginases with IC50s of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1), respectively. OATD-02 abolishes tumor immunosuppression induced by both arginases. OATD-02 can be used for melanoma study. |
|
| DC74621 |
Icalcaprant |
Icalcaprant is a kappa-opioid receptor antagonist. |
|
| DC74622 |
Igermetostat |
Igermetostat is EZH2 inhibitor, used in cancer research in vivo and in vitro. |
|
| DC74623 |
SPC-180002 |
SPC-180002 is a SIRT1/3 dual inhibitor, with IC50 values of 1.13 and 5.41 μM, respectively. SPC-180002 disturbs redox homeostasis via ROS generation, which leads to an increase in both p21 protein stability and mitochondrial dysfunction. SPC-180002 strongly inhibits cell cycle progression and cancer cell growth. SPC-180002 activates the Nrf2 signaling pathway. |
|
| DC74624 |
Tibremciclib |
Tibremciclib is a CDK4 inhibitor with antineoplastic activity. |
|
| DC74625 |
Votoplam |
Votoplam is a gene splicing modulator, used to inhibit Huntington's disease. |
|
| DC74626 |
Lacutoclax |
Lacutoclax is a Bcl-2 inhibitor with antineoplastic activity. |
|
| DC74627 |
NSC89641 |
NSC89641 inhibits MERS-CoV Mpro, with an IC50 value < 3.5 μM. NSC89641 exhibits the high inhibitory potency against SARS-CoV-2 Mpro enzymatic activity, with an IC50 of 3.05 μM. |
|
| DC74628 |
PC-766B |
PC-766B is a macrolide antibiotic. PC-766B is active against Gram-positive bacteria, and some fungi and yeasts, but inactive against Gram-negative bacteria. PC-766B shows antitumor activity against murine tumor cells. PC-766B has weak inhibitory activity against Na+, K+-ATPase. |
|
| DC74629 |
Zevotrelvir |
Zevotrelvir (Compound 52) is a coronavirus inhibitor with IC50 ranges of <0.1 μM and <0.1mM for 229E hCoV and SARS-CoV-23C-like (3CL) proteases, respectively. Zevotrelvir has the potential to study viral infections. |
|
| DC90056 |
PLX-5622 HCl form (water solubility form)
Featured
|
PLX5622 is the HCl salt form of PLX-5622, which has better water solubility.PLX-5622 is a highly selective brain-penetrant CSF1R inhibitor (IC50=0.016 µM; Ki=5.9 nM) allowing for extended and specific microglial elimination, preceding and during pathology development. |
|
| DC60580 |
Endosidin5(ES5)
Featured
|
Endosidine 5 (ES5), is one of the most potent small molecules interferes with recycling endosomes through Annexin A6, thereby promoting the release and expression of mRNA into the cytoplasm. The delivered mRNAs is greatly enhanced via inhibition of endocytic recycling in cells and in live mice. NAV2729 (NAV) and endosidin 5 (ES5), resulted in significant enhancement (1.5–2 folds) of LNP-mediated delivery of Fluc mRNAs. Incubation of NAV and ES5 together caused modest further increases in Fluc expression in comparison to the sole application of either compound. |
|
| DC66114 |
FAPI-46
Featured
|
FAPI46 is a quinoline-based fibroblast activation protein (FAP)-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation. FAPI 46 can be used for tumor imaging of a multitude of different cancers. |
|
| DC60597 |
AZD0780
Featured
|
AZD0780 is the first oral small molecule PCSK9 inhibitor for the treatment of hypercholesterolemia. |
|
| DC66546 |
R-Sirpiglenastat
Featured
|
R-Sirpiglenastat is the R- isomer of Sirpiglenastat(DRP-104).Sirpiglenastat (DRP104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response. |
|
